Moleculin says Cleveland Clinic review finds no significant Annamycin cardiotoxicity in R/R AML

• Moleculin Biotech flagged new pooled cardiac safety findings for its anthracycline Annamycin in relapsed or refractory acute myeloid leukemia, with results set for presentation at European Hematology Association 2026 Congress.
• Independent Cleveland Clinic review of multiple completed trials found no clinically meaningful treatment-related heart toxicity, including in patients treated beyond conventional lifetime exposure limits for standard anthracyclines.
• Analysis showed cardiac function remained stable over treatment, supporting plans to position Annamycin for heavily pretreated patients who often cannot receive further anthracycline therapy due to cardiotoxicity risk.
• Company framed safety profile as a potential differentiator that could expand use in AML salvage settings where current options have limited benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930PRIMZONEFULLFEED9718335) on May 12, 2026, and is solely responsible for the information contained therein.